APC Rabbit Anti-Human ITGA1/CD49a Monoclonal Antibody for Flow Cytometry - P56199

Core Product Specifications and Parameters

Biological Background: ITGA1 Function and Localization

• Integrin alpha-1 (ITGA1), also known as CD49a or VLA-1, is the alpha subunit of the integrin alpha-1/beta-1 receptor that specifically binds laminin and collagen, recognizing the proline-hydroxylated sequence G-F-P-G-E-R in collagen.
• The protein plays a role in anchorage-dependent negative regulation of EGF-stimulated cell growth, linking extracellular matrix adhesion to intracellular signaling pathways.
• ITGA1 is a membrane-spanning glycoprotein with a large extracellular domain, a single transmembrane helix, and a short cytoplasmic tail; it requires divalent cations (calcium and magnesium) for ligand binding.
• The integrin alpha-1 subunit contains multiple repeat domains and disulfide bonds that stabilize its structure, and it undergoes signal peptide cleavage during maturation.
• As a member of the integrin family, ITGA1 is involved in cell adhesion and functions as a receptor, mediating interactions between cells and the extracellular matrix.

Experimental Guidance and Technical Tips

• The immunogen encompasses amino acids 29–1141 of full-length ITGA1, corresponding to the extracellular domain; the antibody is thus suitable for detecting intact cells by flow cytometry.
• For flow cytometry, consider titrating the antibody to determine the optimal staining concentration and ensure proper blocking to minimize non-specific binding.
• This antibody has been validated for use with human samples; its cross-reactivity with other species has not been characterized, so appropriate controls should be included when testing non-human systems.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides a comprehensive selection of IVD raw materials, including validated APC-conjugated anti-ITGA1 antibodies for researchers developing cell adhesion and oncology-related diagnostic assays. Our sourcing platform offers one-stop access to optimized antibody pairs, bulk ancillary reagents, and rare target raw-material procurement, streamlining your transition from early-stage research to clinical application.